{
  "drug_name": "Erythromycin Base, Esters",
  "tradename": "Erythrocin, Ilosone, Erythromycin lactobionate, Eryc, E-mycin, Erythromid",
  "drug_shortage": [
    {
      "preparation": "Injection (lactobionate)",
      "start_date": "2025-04-23",
      "notes": ""
    }
  ],
  "usage_and_dosing": {
    "general": [
      "Erythromycin is the original macrolide antibiotic, first approved in 1952. It is used to treat respiratory tract and skin infections caused by susceptible organisms.",
      "Binds to the 50S ribosomal subunit to interfere with protein synthesis. Mechanism of resistance: methylation of ribosomal target (high level resistance) and activation of efflux pumps (low level resistance).",
      "Available in a variety of pharmaceutical preparations. Conversion: 400 mg erythromycin ethylsuccinate = 250 mg erythromycin base.",
      "Gastroparesis: see Comments.",
      "Caution: numerous drug interactions (see chart below, not all-inclusive)."
    ],
    "adult_dose": {
      "usual_oral_dose": {
          "base": "250-500 mg po q6-12h",
          "ethylsuccinate": "400-800 mg po q6-12h"
      },
      "usual_iv_dose_lactobionate": "500-1000 mg IV q6h (max 4 gm/day)",
      "other_uses": "Colorectal surgery prophylaxis"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "40-50 mg/kg/day (divided q6h)",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "2-4",
    "half_life_esrd": "5-6",
    "dose_renal_function_normal": "250-500 mg po q6h",
    "crcl_or_egfr": "No dosage adjustment for renal impairment",
    "hemodialysis": "No dosage adjustment",
    "capd": "No dosage adjustment",
    "crrt": "No dosage adjustment",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "adverse_effects": [
    "Gastrointestinal: nausea/vomiting (common), diarrhea, C. difficile colitis",
    "Increased LFTs",
    "Confusion, headache",
    "Ototoxicity (with high doses in ESRD)",
    "Combination of erythromycin and a statin can result in elevated statin serum levels and subsequent rhabdomyolysis (Ann Intern Med 2013;158:869).",
    "See QTc prolongation.",
    "See Macrolides, Overview."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "Safety data conflict. Macrolide exposure associated with ↑ risk of spontaneous abortion (1st TM use) and ↑ risk of major birth defects in some studies. Use with caution. 8",
    "lactation": "Safe, monitor infant for GI toxicity",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category. 8: Ref: Pharmacotherapy 2025;45:227"
  },
  "antimicrobial_spectrum": {
    "preferred": [
        "Actinomyces sp.",
        "Arcanobacterium sp.",
        "Campylobacter jejuni",
        "Corynebacterium diphtheriae",
        "Haemophilus ducreyi",
        "Klebsiella granulomatis (granuloma inguinale)",
        "Legionella sp."
    ],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "24-hr AUC/MIC",
    "preparations": "Base tab (250, 500 mg), Delayed-release (DR) tab (250, 333, 500 mg), DR cap (250 mg), Ethylsuccinate tab (400 mg), Ethylsuccinate oral susp (200 mg/5 mL, 400 mg/5 mL), 2% topical gel/pad/soln, 0.5% oph ointment, Lactobionate injection",
    "food_recommendation": "Base no food, DR/ethylsucc ± food",
    "oral_absorption_percent": "18-45",
    "tmax_hr": "DR preps 3",
    "peak_serum_conc_ug_ml": "0.1-2.0 (500 mg base po, SD), 3-4 (500 mg IV, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "70-74",
    "volume_of_distribution_vd_l_kg": "0.6 L/kg",
    "avg_serum_half_life_hr": "2-4",
    "elimination": "Biliary",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "2-13",
    "therapeutic_levels_in_csf": "No",
    "auc_ug_hr_ml": "No data"
  },
  "enzyme_transporter_mediated_interactions": {
      "cyp450s_substrate": ["CYP3A4"],
      "transporters_substrate": ["PGP"],
      "ugts_substrate": [],
      "cyp450s_inhibited": ["CYP3A4"],
      "transporters_inhibited": ["PGP", "OATP1B1"],
      "ugts_inhibited": [],
      "cyp450s_induced": [],
      "transporters_induced": [],
      "ugts_induced": [],
      "impact_on_serum_drug_concentrations": "↑"
  },
  "major_drug_interactions": [
      {"drug": "Alfentanil", "effect": "↑ alfentanil", "management": "Monitor or avoid"},
      {"drug": "Alprazolam", "effect": "↑ alprazolam", "management": "Monitor, adjust dosage"},
      {"drug": "Amiodarone", "effect": "↑ amiodarone", "management": "Monitor or avoid"},
      {"drug": "Amlodipine", "effect": "↑ amlodipine", "management": "Monitor or avoid"},
      {"drug": "Atorvastatin", "effect": "↑ atorvastatin", "management": "Adjust dosage or avoid"},
      {"drug": "Bromocriptine", "effect": "↑ bromocriptine", "management": "Monitor or avoid"},
      {"drug": "Carbamazepine", "effect": "↑ carbamazepine", "management": "Monitor, adjust dosage"},
      {"drug": "Cilostazol", "effect": "↑ cilostazol", "management": "Monitor or avoid"},
      {"drug": "Clozapine", "effect": "↑ clozapine", "management": "Monitor, adjust dosage"},
      {"drug": "Colchicine", "effect": "↑ colchicine", "management": "Monitor, adjust dosage"},
      {"drug": "Cyclosporine", "effect": "↑ cyclosporine", "management": "Monitor or avoid"},
      {"drug": "Digoxin", "effect": "↑ digoxin", "management": "Monitor, adjust dosage"},
      {"drug": "Diltiazem", "effect": "↑ diltiazem", "management": "Monitor or avoid"},
      {"drug": "Disopyramide", "effect": "↑ disopyramide", "management": "Monitor or avoid"},
      {"drug": "Dofetilide", "effect": "↑ dofetilide", "management": "Monitor or avoid"},
      {"drug": "Eplerenone", "effect": "↑ eplerenone", "management": "Monitor, adjust dosage"},
      {"drug": "Ergot alkaloids", "effect": "↑ ergot alkaloid", "management": "Contraindicated"},
      {"drug": "Fexinidazole", "effect": "↓ M1, M2 (fexinidazole) metabolites", "management": "Monitor or avoid"},
      {"drug": "Lovastatin", "effect": "↑ lovastatin", "management": "Contraindicated"},
      {"drug": "Methylprednisolone", "effect": "↑ methylprednisolone", "management": "Monitor"},
      {"drug": "Midazolam", "effect": "↑ midazolam", "management": "Monitor, adjust dosage"},
      {"drug": "Nirmatrelvir/RTV", "effect": "↑ erythromycin", "management": "Monitor, adjust dosage"},
      {"drug": "Phenytoin", "effect": "↑ phenytoin", "management": "Monitor, adjust dosage"},
      {"drug": "Pimozide", "effect": "↑ pimozide", "management": "Contraindicated"},
      {"drug": "Procainamide", "effect": "↑ QT interval", "management": "Monitor or avoid"},
      {"drug": "Quinidine", "effect": "↑ quinidine", "management": "Monitor or avoid"},
      {"drug": "Rifabutin", "effect": "↓ erythromycin, ↑ rifabutin", "management": "Monitor, adjust dosage"},
      {"drug": "Sildenafil", "effect": "↑ sildenafil", "management": "Adjust dosage or avoid"},
      {"drug": "Simvastatin", "effect": "↑ simvastatin", "management": "Contraindicated"},
      {"drug": "Sotalol", "effect": "↑ QT interval", "management": "Monitor or avoid"},
      {"drug": "Tacrolimus", "effect": "↑ tacrolimus", "management": "Monitor or avoid"},
      {"drug": "Theophylline", "effect": "↑ theophylline, ↓ erythromycin?", "management": "Monitor, adjust dosage"},
      {"drug": "Triazolam", "effect": "↑ triazolam", "management": "Monitor, adjust dosage"},
      {"drug": "Valproic acid", "effect": "↑ valproic acid", "management": "Monitor, adjust dosage"},
      {"drug": "Verapamil", "effect": "↑ verapamil", "management": "Monitor or avoid"},
      {"drug": "Vinca alkaloids", "effect": "↑ vinca alkaloid", "management": "Avoid co-administration"},
      {"drug": "Warfarin", "effect": "↑ warfarin", "management": "Monitor INR, adjust dosage"}
  ],
  "comments": [
      "Gastroparesis: Use of erythromycin to stimulate peristalsis is controversial (Expert Opin Pharmacother 2013;14:1171; Eur J Pharmacol 2013;715:10). Despite absence of controlled studies, still used as an alternative agent.",
      "Erythromycin initiates peristalsis by binding to motilin receptors and apparently improves gastric emptying for about 2 weeks. Thereafter the motilin receptors are downregulated and tachyphylaxis ensues.",
      "If used, the recommended IV dose is 1.5-3 mg/kg IV (infused over 45 min) q6h. If oral suspension used, dose is 125 mg po bid.",
      "Reference: Gastroenterol Clin North Am 2015;44:97."
  ]
}
